These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29181185)

  • 41. Prognostic Value of Functional Assessment of Cancer Therapy-General (FACT-G) in Advanced Non-Small-Cell Lung Cancer Treated with Korean Medicine.
    Jeon H; Eo W; Shim B; Kim S; Lee S
    Evid Based Complement Alternat Med; 2020; 2020():2845401. PubMed ID: 32454853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of Outcomes and a Scoring System for Estimating Survival in Patients Treated With Radiotherapy for Metastatic Spinal Cord Compression From Small-Cell Lung Cancer.
    Rades D; Motisi L; Veninga T; Conde-Moreno A; Cacicedo J; Schild SE
    Clin Lung Cancer; 2019 Jul; 20(4):322-329. PubMed ID: 31155476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017.
    Nakahara Y; Hosomi Y; Shibuya M; Mitsufuji H; Katagiri M; Naoki K; Soejima K; Nogami N; Nagase S; Nishikawa M; Minato K; Takiguchi Y; Seki N; Yamada K; Seto T; Okamoto H
    Mol Clin Oncol; 2019 Oct; 11(4):349-353. PubMed ID: 31475062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort.
    Conen K; Hagmann R; Hess V; Zippelius A; Rothschild SI
    J Cancer; 2016; 7(14):2110-2116. PubMed ID: 27877227
    [No Abstract]   [Full Text] [Related]  

  • 45. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
    Santoni M; Conti A; Procopio G; Porta C; Ibrahim T; Barni S; Guida FM; Fontana A; Berruti A; Berardi R; Massari F; Vincenzi B; Ortega C; Ottaviani D; Carteni G; Lanzetta G; De Lisi D; Silvestris N; Satolli MA; Collovà E; Russo A; Badalamenti G; Luzi Fedeli S; Tanca FM; Adamo V; Maiello E; Sabbatini R; Felici A; Cinieri S; Montironi R; Bracarda S; Tonini G; Cascinu S; Santini D
    J Exp Clin Cancer Res; 2015 Feb; 34(1):10. PubMed ID: 25651794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis.
    Tsuda Y; Nakagawa T; Shinoda Y; Kanatani A; Kawai T; Taguchi S; Yamada Y; Sawada R; Kume H; Homma Y; Tanaka S; Kawano H
    Int J Clin Oncol; 2017 Jun; 22(3):548-553. PubMed ID: 28044212
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic Value of Ferritin-to-Hemoglobin Ratio in Patients with Advanced Non-Small-Cell Lung Cancer.
    Lee S; Jeon H; Shim B
    J Cancer; 2019; 10(7):1717-1725. PubMed ID: 31205527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.
    Hoang T; Xu R; Schiller JH; Bonomi P; Johnson DH
    J Clin Oncol; 2005 Jan; 23(1):175-83. PubMed ID: 15625371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries.
    Hoefeler H; Duran I; Hechmati G; Garzon Rodriguez C; Lüftner D; Ashcroft J; Bahl A; Atchison C; Wei R; Thomas E; Lorusso V
    J Bone Oncol; 2014 May; 3(2):40-8. PubMed ID: 26909296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical features and prognosis in 104 colorectal cancer patients with bone metastases].
    Hong RX; Lin QJ; Luo J; Dai Z; Wang WN
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):787-91. PubMed ID: 24378104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
    Käsmann L; Taugner J; Eze C; Roengvoraphoj O; Dantes M; Gennen K; Karin M; Petrukhnov O; Tufman A; Belka C; Manapov F
    Anticancer Res; 2019 Sep; 39(9):5077-5081. PubMed ID: 31519618
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics of clinical N0 metastatic non-small cell lung cancer.
    Tamura T; Kurishima K; Watanabe H; Shiozawa T; Nakazawa K; Ishikawa H; Satoh H; Hizawa N
    Lung Cancer; 2015 Jul; 89(1):71-5. PubMed ID: 25913230
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
    Somer RA; Sherman E; Langer CJ
    Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer.
    Delea TE; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
    J Thorac Oncol; 2006 Jul; 1(6):571-6. PubMed ID: 17409919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
    Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
    J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
    Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
    J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
    Bhowmik D; Song X; Intorcia M; Gray S; Shi N
    Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.